Russian scientists hail results of Covid-19 vaccine trial

Published July 15, 2020
A larger scale trial, intended to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russia in mid-August. —  AP
A larger scale trial, intended to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russia in mid-August. — AP

Russian scientists hailed the results of their first clinical trial of a potential coronavirus vaccine on Wednesday, saying it had been proved safe and that volunteers had developed an immune response.

Speaking to a crowded room without wearing masks, three of 18 volunteers monitored over a month at the Sechenov University said they all had experienced few side effects.

A larger scale trial, intended to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russia in mid-August.

More than 100 possible vaccines are being developed and tested around the world to try to stop the pandemic.

Of 19 in human trials, only two are in the final Phase III — one by China's Sinopharm and another by AstraZeneca and the University of Oxford.

“We were primarily testing for safety,” Elena Smolyarchuk, a department director at Sechenov University and one of the coordinators of the trial, said.

“On non-specific immunity we can only talk about preliminary results. These show a good, positive tendency, a strengthening of non-specific immunity,” she said.

However, any final conclusions about the immune response among the volunteers will be drawn by the Gamaleya Institute, which developed the vaccine, and are expected towards the end of the month.

Russia's health ministry will then decide whether to register the vaccine and begin a larger scale trial, Smolyarchuk said.

The vaccine is administered in two doses and consists of two serotypes of the human adenovirus, each carrying an S-antigen of the new coronavirus, which enter human cells and produce an immune response, Smolyarchuk said.

It was first tested on primates and then administered to the volunteers on June 18.

"The platform used for the vaccine was developed by Russian scientists over two decades and had formed the basis for several vaccines in the past, including three against Ebola," the Sechenov University's Vadim Tarasov said.

The defence ministry, which conducted a parallel trial of the same vaccine on a separate set of 20 volunteers, also said on Wednesday the group had been discharged.

“It's not scary anymore,” Yuriy, a soldier and volunteer, said in a video shared by the Ministry of Defence.

Opinion

Blood and oil
Updated 03 Mar 2021

Blood and oil

Uncle Sam is only mildly miffed with the Saudis.
A twist to behold
02 Mar 2021

A twist to behold

The issue here is that the Islamabad election is but a smaller story arc.

Editorial

Vaccine challenges
Updated 03 Mar 2021

Vaccine challenges

THE last few months have seen several countries rolling out vaccination drives against the novel coronavirus, which...
03 Mar 2021

Rising prices

CONTRARY to government projections and market expectations, the cost of goods and services for the public during...
03 Mar 2021

Myanmar crisis

THE political crisis triggered by the military coup in Myanmar on Feb 1 is worsening, with the generals refusing to...
SC on Senate polls
Updated 02 Mar 2021

SC on Senate polls

THE Supreme Court has declared in its short order on the reference sent by the president under Article 186 of the...
02 Mar 2021

Khashoggi report

THE grisly 2018 murder of Saudi journalist Jamal Khashoggi in the kingdom’s Istanbul consulate shocked people...
02 Mar 2021

Heritage trail

THE heritage trail project in central Punjab, inaugurated by Prime Minister Imran Khan on Sunday in Jhelum district,...